Table 1 Characteristics of guidelines included in this study
Title | Year of publication | Country/region | Level of development | Organization | Authors number | Number of references | Type of guideline |
|---|---|---|---|---|---|---|---|
EGFR inhibitor-associated cutaneous toxicities: An Evolving Paradigm in Clinical Management [21] | 2007 | USA | International | Not specified | 6 | 58 | CBG |
Clinical significance and treatment of skin rash from erlotinib in NSCLC patients: results of an Experts Panel Meeting [22] | 2008 | Italy | National | Not specified | 15 | 37 | CBG |
An interdisciplinay consensus on managing skin reactions associated with EGFRI [23] | 2008 | USA | National | Not specified | 3 | 31 | CBG |
Expert consensus on the management of erlotinib-associated cutaneous toxicity in the UK [24] | 2009 | UK | National | Not specified | 9 | 28 | CBG |
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities [25] | 2011 | Canada, USA France, | International | Not specified | 16 | 55 | CBG |
Management of cutaneous side effects of EGFR inhibitors: recommendation from a German expert panel [26] | 2011 | Germany | National | Not specified | 12 | 36 | CBG |
Clinical practice guideline for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities [27] | 2011 | France, Italy, USA,Singapore | International | Skin toxicity study group (STSG) | 7 | 114 | EBG |
Interdisciplinary management of EGFR-inhibitor- induced skin reactions: a German expert opinion [28] | 2011 | Germany | National | Not specified | 12 | 81 | CBG |
Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy [29] | 2011 | Italy | National | Not specified | 7 | 68 | CBG |
Management of cutaneous adverse events induced by anti-EGFR: a French interdisciplinary therapeutic algorithm [30] | 2012 | France | National | Not specified | 21 | 32 | CBG |
Clinical practice guideline for the prevention and treatment of rash in patients treated with EGFR inhibitor therapies [31] | 2012 | Canada | Regional | TGHNTT | Not specified | 73 | CBG |
Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendation from a multinational expert panel [32] | 2013 | Europe | International | No specified | 7 | 48 | CBG |
Management of the adverse events of afatinib: a consensus of the recommendations from the Spanish expert panel [33] | 2015 | Spain | National | No specified | 8 | 34 | CBG |
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK [34] | 2015 | UK | National | No specified | 13 | 46 | CBG |
Practical recommendations for rash and diarrhea management in Indian patients treated with TKI for the treatment of NSCLC [35] | 2016 | India | National | No specified | 11 | 7 | CBG |
Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy: update of the Italian expert recommendations [36] | 2016 | Italy | National | No specified | 7 | 53 | CBG |
BRAF/MEK Inhibitor Therapy: Consensus Statement on Managing Adverse Events and Potential Drug Interactions [37] | 2017 | USA | National | The Melanoma Nursing Initiative | 2 | 33 | CBG |
Prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities [38] | 2017 | China | Regional | TDA | 6 | 33 | CBG |
Putting evidence into practice: skin reactions [39] | 2017 | USA | National | ONS | 10 | 98 | EBG |